Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 432-690-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Analogue substance tested; GLP study using standard method;
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 000
- Report date:
- 2000
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: Annex V (Developmental toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
time mated females from
- Source:Covance Research Products, Kalamazoo USA
- Age at study initiation: no data
- Weight at study initiation:no data
- Fasting period before study: none
- Housing: individually
- Diet : 170 g/d
- Water (e.g. ad libitum): ad lib
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19,4 - 21,1 ( 67 - 70 F)
- Humidity (%): 53-69
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5% carboxymethylcellulose
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The test material was mixed to the 5 % CMC in water weekly to give an application volume of 10 ml/kg bw.
VEHICLE
- Concentration in vehicle: 0,5 % CMC in water
- Amount of vehicle (if gavage): 10 ml/kg bw
- Purity: no data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- no data
- Details on mating procedure:
- no data; animals were purchased as "time-mated"
- Duration of treatment / exposure:
- day 7 through day 28 of gestation;
- Frequency of treatment:
- once daily
Dosing regime: 7 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
100 mg/kg bw
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
400 mg/kg bw
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
800 mg/kg bw
Basis:
nominal conc.
- No. of animals per sex per dose:
- 25 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Pilot study
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
- Cage side observations: mortality, sign of toxicity, other findings were recorded on the day of observation
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:daily
BODY WEIGHT: Yes
- Time schedule for examinations: daily
FOOD CONSUMPTION : Yes
- Food consumption for each animal determined and mean diet consumption calculated as g food/kg body weight/day: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #29
- Organs examined: general necropsy; special attention to: Uterus + contents, mammary glands - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter - Statistics:
- yes
Group pairwise comparisons for each endpoint and time period (Levene's test, Dunnett's test & Welch test with Bonferroni correction)
Arcsine-Square root transformation for perdent values
Chi square test for sex distribution
Covariate analysis for each endpoint and time period litter size was used as a covariate
Kruskal-Wallis test for external and visceral abnormalities per litter
Pearson Chi-Square test for litter incidence for individual and total malformations.
Descriptive statistics: means + standard deviations - Historical control data:
- no data
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Eight females from the 800 mg/kg/day group died during the study and an additional one was terminated in extremis;
treatment-related clinical signs at this dose included convulsions, decreased defaecation, soft stool, discoloured faeces and reddish fluid in the refuse pan. As a result of the excessive mortality and maternal toxicity six females were selectively euthanised. Only three females survived to Day 29. Seven females in this treatment group aborted during the study and this effect was considered to be treatment- related.
All further information refers to the control, 100 and 400 mg/kg/day groups only.
Two females in the control group died on gestation day 23 and one from the 400 mg/kg/day grou died on gestation day 11. These deaths were not considered to be treatment-related and were due to intubation errors or mechanical injury.
Two females from the 400 mg/kg/day delivered early, this was considered to be treatment-related. Increased incidences of soft stool and decreased defaecation compared to the control group were also observed at 400 mg/kg/day. One female from the 100 mg/kg/day group aborted during the study, this effect was not thought to be treatment-related, as necropsy revealed injuries consistent with intubation error. One female from the the 400 mg/kg/day group aborted during the study, this effect was however considered to be treatment-related.
No treatment-related effects were observed on group mean bodyweight, bodyweight gain or food consumption at 100 or 400 mg/kg/day. Statistically significant differences were not observed in mean gravid uterine weights. There were no treatment-related internal findings noted at scheduled necropsy. Pregnancy rates were similar for each treatment group.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (nominal)
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 400 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes. Remark: secondary effects to maternal toxicity
Details on embryotoxic / teratogenic effects:
Effects on fetus - Gross:
No significant differences between treated or control animals were observed in the numbers of viable foetuses, litter size, pre-implantation losses or numbers of corpora lutea per dam. There were no treatment-related effects on the sex ratio of foetuses. A statistically significant decrease in male (8%) and female (8%) foetal bodyweight was observed at 400 mg/kg/day, resulting in a statistically significant decrease (8.7%) in combined sex foetal bodyweight at this dose. These changes may have been secondary to the maternal toxicity observed at this dose.
One foetus from each of the 100 and 400 mg/kg/day groups was observed with different major external abnormalities, but these were not considered to be toxicologically significant.
Effects on fetus - Soft tissue:
The only soft tissue malformation observed was gallbladder agenesis where 1 foetus in the 400 mg/kg/day group was affected, however the litter incidence was within historical control values. A number of soft tissue developmental variations (hypoplasia of the gall bladder, azygous lobe of lung absent and haemorrhagic iris) were also noted but these were not dose-related, were observed at similar frequencies in historical controls and therefore were not considered to be treatment-related. The litter incidence (9%) of the developmental variation, haemorrhagic iris, in the 400 mg/kg/day group was above the laboratory historical control value (6%) for this strain; this effect may have been secondary to the maternal toxicity observed at this dos e.
Effects on fetus - Skeletal:
No treatment-related increases in skeletal malformations or variations were observed in 100 or 400 mg/kg/day groups. Any skeletal malformations and developmental variations that were recorded were not dose-related, spontaneous in origin or were observed at similar frequencies in historical controls and therefore were not considered to be treatment-related.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The analogue substance 2 (refer to IUCLID chapter 13) did not cause direct developmental effects in rabbits treated from day 6 to 28 of gestation. Thus, the registered substance is also not expected to directly influence the prenatal development of rabbit offspring. Effects of maternal toxicity at high doese cannot be excluded.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.